Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

Phase 2

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: BI 1467335
Drug: Placebo

First Posted Date: 2017-05-25

Last Posted Date: 2020-06-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 114

Registration Number: NCT03166735

Locations: 🇨🇦
Toronto Liver Centre, Toronto, Ontario, Canada
🇳🇱
Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
🇺🇸
National Research Institute, Los Angeles, California, United States

and more 40 locations

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

Phase 1

Terminated

Conditions: Neoplasms
Neoplasm Metastasis
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BI 891065
Drug: BI 754091

First Posted Date: 2017-05-25

Last Posted Date: 2024-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT03166631

Locations: 🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: BI 690517
Drug: Eplerenone
Drug: Placebo

First Posted Date: 2017-05-24

Last Posted Date: 2020-09-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 62

Registration Number: NCT03165240

Locations: 🇩🇰
Steno Diabetes Center Copenhagen, Gentofte, Denmark
🇩🇰
Bispebjerg og Frederiksberg Hospital, København NV, Denmark
🇩🇰
Copenhagen University Hospital, Rigshospitalet, København Ø, Denmark

and more 37 locations

Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiolto® Respimat®

First Posted Date: 2017-05-24

Last Posted Date: 2020-04-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1351

Registration Number: NCT03165045

Locations: 🇩🇪
Dr. Urban, Berlin, Germany
🇩🇪
Dr. Kassik, Bitterfeld-Wolfen, Germany
🇩🇪
Praxis B. Metzlaff, Büchen, Germany

and more 103 locations

This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)

Phase 1

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: BI 685509
Drug: Placebo

First Posted Date: 2017-05-24

Last Posted Date: 2020-01-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 75

Registration Number: NCT03165227

Locations: 🇺🇸
Indago Research and Health Center, Hialeah, Florida, United States
🇺🇸
Research by Design, LLC, Chicago, Illinois, United States
🇺🇸
Houston Clinical Research Associates, Houston, Texas, United States

and more 32 locations

This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1467335
Drug: Placebo

First Posted Date: 2017-05-18

Last Posted Date: 2021-06-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 48

Registration Number: NCT03159455

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan
🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib
Drug: pembrolizumab

First Posted Date: 2017-05-17

Last Posted Date: 2021-02-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT03157089

Locations: 🇫🇷
HOP Côte de Nacre, Caen, France
🇫🇷
HOP Le Mans, Le Mans, France
🇺🇸
Baptist Health Medical Group, Lexington, Kentucky, United States

and more 10 locations

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Neoplasms

Interventions: Drug: BI 754111
Drug: BI 754091

First Posted Date: 2017-05-17

Last Posted Date: 2023-06-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 172

Registration Number: NCT03156114

Locations: 🇪🇸
Hospital Universitari Dexeus, Barcelona, Spain
🇪🇸
Hospital Politècnic La Fe, Valencia, Spain
🇬🇧
Sarah Cannon Research Institute, London, United Kingdom

and more 12 locations

Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Rifampicin

First Posted Date: 2017-05-12

Last Posted Date: 2024-03-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT03151499

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: Dabigatran Etexilate
Drug: Rabeprazol sodium

First Posted Date: 2017-05-08

Last Posted Date: 2019-01-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT03143166

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy